On January 5, 2026, AstraZeneca announced a multi-year collaboration with BostonGene to integrate the company’s multimodal AI foundation model for tumor and immune biology into early-stage oncology trials. Under the agreement, AstraZeneca will deploy BostonGene’s platform—combining cell-free RNA profiling, tumor microenvironment analytics and deep learning—to generate patient-level predictions of safety and efficacy. By incorporating these insights into trial design, the partners aim to shorten development timelines by up to 20% and reduce the probability of late-stage attrition, according to internal modeling. The collaboration will initially focus on three asset programs in solid tumors, with options to expand across AstraZeneca’s broader oncology portfolio.

In mid-December 2025, AstraZeneca reported positive topline results from the TULIP-SC Phase 3 trial evaluating a self-injectable formulation of Saphnelo (anifrolumab) in systemic lupus erythematosus. The trial enrolled over 450 patients across North America and Europe and demonstrated a 56.2% reduction in validated disease activity scores at week 52, compared with 37.1% in the placebo arm (p<0.0001). Safety analyses showed comparable rates of serious adverse events (8.3% versus 7.9%), with no new safety signals identified. Saphnelo is already approved in more than 70 countries and has been administered to over 40,000 patients to date; the new self-injectable format is expected to expand patient access and support label extensions in high-growth markets.